ZA200303887B - Novel pyridine-substituted pyrazolopyridine derivatives. - Google Patents
Novel pyridine-substituted pyrazolopyridine derivatives. Download PDFInfo
- Publication number
- ZA200303887B ZA200303887B ZA200303887A ZA200303887A ZA200303887B ZA 200303887 B ZA200303887 B ZA 200303887B ZA 200303887 A ZA200303887 A ZA 200303887A ZA 200303887 A ZA200303887 A ZA 200303887A ZA 200303887 B ZA200303887 B ZA 200303887B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- compound
- compounds
- medicaments
- production
- Prior art date
Links
- -1 pyridine-substituted pyrazolopyridine Chemical class 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 86
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims description 5
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 230000002140 halogenating effect Effects 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 10
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000460 chlorine Chemical group 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- 150000005229 pyrazolopyridines Chemical class 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- LQCFFAGUCURQEC-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carboximidamide Chemical compound C12=NC=CC=C2C(C(=N)N)=NN1CC1=CC=CC=C1F LQCFFAGUCURQEC-UHFFFAOYSA-N 0.000 description 3
- PIAJEGZQMONLLM-UHFFFAOYSA-N 3-(4,6-dichloro-5-pyridin-4-ylpyrimidin-2-yl)-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine Chemical compound FC1=CC=CC=C1CN1C2=NC=CC=C2C(C=2N=C(Cl)C(=C(Cl)N=2)C=2C=CN=CC=2)=N1 PIAJEGZQMONLLM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010078321 Guanylate Cyclase Proteins 0.000 description 3
- 102000014469 Guanylate cyclase Human genes 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- OOMBRKGIWITBLL-UHFFFAOYSA-N (2-fluorophenyl)methylhydrazine Chemical compound NNCC1=CC=CC=C1F OOMBRKGIWITBLL-UHFFFAOYSA-N 0.000 description 2
- CSUUGTRFBZTTQW-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carbonitrile Chemical compound FC1=CC=CC=C1CN1C2=NC=CC=C2C(C#N)=N1 CSUUGTRFBZTTQW-UHFFFAOYSA-N 0.000 description 2
- GWDSAMDSGSEPRH-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carboxamide Chemical compound C12=NC=CC=C2C(C(=O)N)=NN1CC1=CC=CC=C1F GWDSAMDSGSEPRH-UHFFFAOYSA-N 0.000 description 2
- VAIBMQLMFYXTLJ-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5-pyridin-4-ylpyrimidin-4-amine Chemical compound NC1=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=C1C1=CC=NC=C1 VAIBMQLMFYXTLJ-UHFFFAOYSA-N 0.000 description 2
- HLQSLDJTORKWDM-UHFFFAOYSA-N 2-[3-(dimethylaminomethylidene)-2h-pyridin-2-yl]acetonitrile Chemical compound CN(C)C=C1C=CC=NC1CC#N HLQSLDJTORKWDM-UHFFFAOYSA-N 0.000 description 2
- OIPHWUPMXHQWLR-UHFFFAOYSA-N 2-pyridin-3-ylacetonitrile Chemical compound N#CCC1=CC=CN=C1 OIPHWUPMXHQWLR-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- OQQVFCKUDYMWGV-UHFFFAOYSA-N [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 OQQVFCKUDYMWGV-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- KZVKXYSMYGMEPB-UHFFFAOYSA-N ethyl 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carboxylate Chemical class C12=NC=CC=C2C(C(=O)OCC)=NN1CC1=CC=CC=C1F KZVKXYSMYGMEPB-UHFFFAOYSA-N 0.000 description 2
- XGTZSVQFCSDHEK-UHFFFAOYSA-N ethyl 3-cyano-2-oxopropanoate Chemical class CCOC(=O)C(=O)CC#N XGTZSVQFCSDHEK-UHFFFAOYSA-N 0.000 description 2
- DVWGQBBJLJWPKJ-UHFFFAOYSA-N ethyl 5-amino-1-[(2-fluorophenyl)methyl]pyrazole-3-carboxylate Chemical compound N1=C(C(=O)OCC)C=C(N)N1CC1=CC=CC=C1F DVWGQBBJLJWPKJ-UHFFFAOYSA-N 0.000 description 2
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WSKGRWHECMNHBT-UHFFFAOYSA-N methyl 1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridine-3-carboximidate Chemical compound C12=NC=CC=C2C(C(=N)OC)=NN1CC1=CC=CC=C1F WSKGRWHECMNHBT-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002883 vasorelaxation effect Effects 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- XPNGNIFUDRPBFJ-UHFFFAOYSA-N (2-methylphenyl)methanol Chemical compound CC1=CC=CC=C1CO XPNGNIFUDRPBFJ-UHFFFAOYSA-N 0.000 description 1
- BYVRSDSZLMZNPV-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-hydroxy-5-pyridin-4-yl-1H-pyrimidin-6-one Chemical compound OC1=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC(O)=C1C1=CC=NC=C1 BYVRSDSZLMZNPV-UHFFFAOYSA-N 0.000 description 1
- DIEJGUHCRDQSFN-UHFFFAOYSA-N 2-[4-(dimethylaminomethylidene)-3h-pyridin-2-yl]acetonitrile Chemical compound CN(C)C=C1CC(CC#N)=NC=C1 DIEJGUHCRDQSFN-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- BMVSAKPRNWZCPG-UHFFFAOYSA-N 2-pyridin-4-ylacetonitrile Chemical compound N#CCC1=CC=NC=C1 BMVSAKPRNWZCPG-UHFFFAOYSA-N 0.000 description 1
- HQVNVYFIPYMSHH-UHFFFAOYSA-N 3-(dimethylamino)-2-pyridin-2-ylprop-2-enenitrile Chemical compound CN(C)C=C(C#N)C1=CC=CC=N1 HQVNVYFIPYMSHH-UHFFFAOYSA-N 0.000 description 1
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HWYBMGUNWYDSPJ-UHFFFAOYSA-N diethyl 2-pyridin-4-ylpropanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=NC=C1 HWYBMGUNWYDSPJ-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XRKMNJXYOFSTBE-UHFFFAOYSA-N disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+4].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] XRKMNJXYOFSTBE-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- FVGUUJNEJJPLCS-UHFFFAOYSA-N pyridine-3-carboximidamide Chemical compound NC(=N)C1=CC=CN=C1 FVGUUJNEJJPLCS-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
New pyridine-substituted pvrazolopvridine derivatives
The present invention relates to new chemical compounds which stimulate soluble guanylate cyclase, their preparation and their use as medicaments, in particular as medicaments for the treatment of cardiovascular diseases.
One of the most important cellular transmission systems in mammals is cyclic guanosine monophosphate (cGMP). Together with nitrogen monoxide (NO) which is released from the endothelium and transmits hormonal and mechanical signals, it forms the NO/cGMP system. The guanylate cyclases catalyse the biosynthesis of cGMP from guanosine triphosphate (GTP). The representatives of this family known hitherto can be divided into two groups according to structural features and according to the nature of the ligands: the particulate guanylate cyclases, which can be stimulated by natriuretic peptides, and the soluble guanylate cyclases, which can be stimulated by NO. The soluble guanylate cyclases consist of two subunits and very highly probably contain one haem per heterodimer, which is a part of the regulatory centre. This has a central importance for the activation mechanism. NO can bind to the iron atom of the haem and thus markedly increase the activity of the enzyme.
Haem-free preparations on the other hand, cannot be stimulated by NO. CO is also able to attack at the central iron atom of the haem, where the stimulation by CO is markedly lower than that by NO.
Owing to the formation of cGMP and the regulation of phosphodiesterases, iron channels and protein kinases resulting therefrom, guanylate cyclase plays a crucial role in different physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, platelet aggregation and adhesion and neuronal signal transmission, and in diseases which are based on a disturbance of the abovementioned processes. Under pathophysiological conditions, the NO/cGMP system may be suppressed, which can lead, for example, to high blood pressure, platelet activation, increased cell proliferation, endothelial dysfunction,
atherosclerosis, angina pectoris, cardiac insufficiency, thromboses, stroke and myocardial infarct.
An NO-independent possibility of treatment for diseases of this type, which is targeted at influencing the cGMP signal pathway in organisms, is a promising approach on account of the high efficiency and low side effects which are to be expected.
For therapeutic stimulation of the soluble guanylate cyclase, hitherto exclusively compounds such as organic nitrates have been used, whose action is based on NO.
This is formed by bioconversion and activates the soluble guanylate cyclase by attacks on the central iron atom of the haem. Besides the side effects, the crucial disadvantages of this manner of treatment includes the development of tolerance.
In recent years, a few substances have been described which stimulate soluble guanylate cyclase directly, i.e. without prior release of NO, for example 3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole (YC-1, Wu et al., Blood 84 (1994), 4226; Miilsch et al., Br. J. Pharmacol. 120 (1997), 681), Fatty acids (Goldberg et al.,
J. Biol. Chem. 252 (1977), 1279), diphenyliodonium-hexafluorophosphate (Pettibone et al., Eur. J. Pharmacol. 116 (1985), 307), isoliquiritigenin (Yu et al., Brit. J.
Pharmacol. 114 (1995), 1587) and various substituted pyrazole derivatives (WO 98/16223).
Furthermore, pyrazolopyridine derivatives have been described as stimulators of soluble guanylate cyclase in WO 98/16507, WO 98/23619, WO 00/06567,
WO 00/06568, WO 00/06569 and WO 00/21954. In these patent applications, pyrazolopyridines are also described which have a pyrimidine radical in the 3 position.
Compounds of this type have a very high in vitro activity with respect to the stimulation of soluble guanylate cyclase. However, it has been seen that these compounds have some disadvantages with respect to their in vivo properties, for example their behaviour in the liver, their pharmacological behaviour, their dose-response relationship or their metabolization pathway.
It was therefore the object of the present invention to provide further pyrazolopyridine derivatives which act as stimulators of soluble guanylate cyclase, but which do not have the abovementioned disadvantages of the compounds from the prior art.
This object is achieved according to the present invention by the compounds according to Claim 1. These new pyrazolopyridine derivatives are distinguished by a pyrimidine radical in the 3 position which has a certain substitution pattern, namely a pyridine radical in the 5 position of the pyrimidine ring and an amino group in the 4 position of the pyrimidine ring.
Specifically, the present invention relates to the compounds of the formula (I) =
R—\ N
AN
N 4 ~3 7 M
N_ %
NT N
0 in which
R' represents 4-pyridinyl or 3-pyridinyl;
R? represents H, NH; or halogen; and salts, isomers and hydrates thereof.
In an alternative embodiment, the present invention relates to compounds of the formula (I) in which
R' represents 4-pyridinyl or 3-pyridinyl;
R’ represents H, NH; or CI, and salts, isomers and hydrates thereof.
In a further alternative embodiment, the present invention relates to compounds of the formula (I) in which
R' represents 4-pyridinyl or 3-pyridinyl;
R’> represents H; and salts, isomers and hydrates thereof.
The compounds of the formula (I) according to the invention can also be present in the form of their salts. In general, salts with organic or inorganic bases or acids may be mentioned here.
In the context of the present invention, physiologically acceptable salts are preferred.
Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts, for example, are those with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, p-toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
Physiologically acceptable salts can likewise be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group. Those particularly preferred are, for example, sodium, potassium, magnesium or calcium salts, and also ammonium salts which are derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
The compounds according to the invention can be present in tautomeric forms. This 1s known to the person skilled in the art, and forms of this type are likewise included by the scope of the invention.
The compounds according to the invention can furthermore occur in the form of their possible hydrates. 135
Within the scope of the invention, halogen represents fluorine, chlorine, bromine and iodine.
The compounds of the formula (I) according to the invention can be prepared by the reaction of the compound of the formula (II)
NH
HN
=I
N \_ “N N (1)
F j
A) with a compound of the formula (III)
CN
NTN
R' (II) where
R is as defined above; if appropriate in an organic solvent, with heating to give the compound of the formula (I); or
B) with a compound of the formula (IV) @) 0 007 oc (IV)
R! where
R! is as defined above; in an organic solvent, with heating to give compounds of the formula (V) 0
Na N
PW
MV)
N
NTN
— OH
HO ,
R where
R' is as defined above; subsequently with a halogenating agent to form compounds of the formula (VI)
F
N
CT
PNY vi)
N
NT \ ) —_— R
R? :
R . where
R' is as defined above;
R’ represents halogen; and also finally with aqueous ammonia solution with heating under elevated pressure.
The compound of the formula (II) can be prepared according to the following reaction scheme:
F
F
“¢ X
N
= * AN SN 0 se HN \_/
NH, 0 (Na salt) 'e) N— q ) ’ ar > No —_— N
N N N ~N 74 N
CL 7 \_} H — 0 —_ / — N
The compound of the formula (II) is obtainable in a multi-stage synthesis from the sodium salts of ethyl cyanopyruvate, which is known from the literature (Borsche and
Manteuffel, Liebigs. Ann. Chem. 1934, 512, 97). By reaction thereof with 2-fluorobenzylhydrazine with heating and under a protective gas atmosphere in an inert solvent such as dioxane, ethyl 5-amino-1-(2-fluorobenzyl)pyrazole- 3-carboxylate is obtained, which cyclizes by means of reaction with dimethylaminoacrolein in the acidic medium under a protective gas atmosphere and with heating to give the corresponding pyridine derivative. This pyridine derivative, ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate, is converted by means of a multi-stage sequence, consisting of conversion of the ester into the corresponding amide using ammonia, dehydration using a dehydrating agent such as trifluoroacetic anhydride to give the corresponding nitrile derivative, reaction of the nitrile derivative with sodium ethoxide and final reaction with ammonium chloride, into the compound of the formula (II).
The compounds of the formula (II) can be prepared from the compounds t-butoxybis(dimethylamino)methane and 4-pyridylacetonitrile or
3-pyridylacetonitrile, which are commercially obtainable (e.g. from Aldrich), by reaction of these reactants, preferably in equimolar amounts, preferably at normal pressure and with stirring of the reaction solution for a number of hours, for example 2 hours, at elevated temperature, for example 60-130°C, preferably 80-120°C, in particular 100°C.
The reaction of the compounds of the formulae (II) and (III) to give the compounds of the formula (I) can be carried out by use of the reactants in equimolar amounts or using the compound of the formula (III) in a slight excess in an organic solvent, for example a hydrocarbon, preferably an aromatic hydrocarbon and in particular xylene, preferably in the presence of 0.1-1 equivalent, preferably 0.3 equivalent, of a Lewis acid such as BF;Et;,O or trimethylsilyl trifluorosulphonate (TMSOTY), preferably at normal pressure and with stirring of the reaction solution for a number of hours, for example 12 hours, at elevated temperature, for example 80-160°C, preferably 100-150°C, in particular 140°C.
The compounds of the formula (IV) are commercially obtainable (for example from
Mercachem) or are preparable in a way known to one skilled in the art.
The conversion of the compounds of the formulae (II) and (IV) into the compounds of the formula (V) can be carried out by using the reactants in equimolar amounts or by using the compound of the formula (IV) in a slight excess in an organic solvent, for example a hydrocarbon, preferably an aromatic hydrocarbon and especially toluene, preferably at atmospheric pressure and stirring the reaction solution for several hours, for example 12 hours, at elevated temperature, for example 80-160°C, preferably 100-150°C, especially 140°C.
The conversion of the compounds of the formula (V) into compounds of the formula (VI) can be carried out by reaction of the compounds of the formula (V) with a halogenating agent, optionally in an organic solvent customarily used for such reactions, for example dimethylformamide (DMF), preferably at atmospheric pressure and stirring of the reaction solution for several hours, for example 3 hours, at elevated temperature, for example 80-160°C, preferably 100-120°C. It is preferable according to the invention to use POCIl; as halogenating agent.
The conversion of the compounds of the formula (VI) into the compounds of the formula (I) according to the invention can be carried out by reaction of the compounds of the formula (VI) with aqueous ammonia solution preferably at elevated pressure, for example by conducting the reaction in an autoclave so that the reaction takes place under the autogenous pressure of the reaction mixture, and stirring of the reaction solution for several hours, for example 12 hours, at elevated temperature for example 80-160°C, preferably 100-150°C, especially 140°C.
The compounds of the formula (I) according to the invention show an unforeseeable, valuable spectrum of pharmacological activity. : The compounds of the formula (I) lead to vasorelaxation, inhibition of platelet aggregation and to a lowering of blood pressure and to an increase in the coronary blood flow. These actions are mediated via direct stimulation of soluble guanylate cyclase and an intracellular cGMP increase. Moreover, the compound of the formula (I) according to the invention potentiates the action of substances which increase the cGMP level, for example EDRF (endothelium-derived relaxing factor), NO donors, protoporphyrin IX, arachidonic acid or phenylhydrazine derivatives.
They can therefore be employed in medicaments for the treatment of cardiovascular diseases, for example for the treatment of high blood pressure and cardiac insufficiency, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, of arrthythmias, for the treatment of thromboembolic diseases and ischaemias such as myocardial infarct, stroke, transitory and ischaemic attacks, peripheral circulatory disorders, prevention of restenoses such as after thrombosis therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA), bypass and also for the treatment of arteriosclerosis,
asthmatic conditions and diseases of the urogenital system such as prostate hypertrophy, erectile dysfunction, female sexual dysfunction, osteoporosis, gastroparesis and incontinence.
The compounds of the formula (I) described in the present invention are also active compounds for the control of diseases in the central nervous system which are characterized by disturbances of the NO/cGMP system. In particular, they are suitable for improving the perception, concentration powder, learning power or memory power after cognitive disorders, such as occur, in particular, in situations/diseases/syndromes such as mild cognitive impairment, age-associated learning and memory disorders, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia which occurs after strokes (post-stroke dementia), post-traumatic craniocerebral trauma, general concentration disorders, concentration disorders in children with learning and memory problems, Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, dementia with degeneration of the frontal lobes including Pick’s dementia, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyolateral sclerosis (ALS),
Huntington's disease, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff psychosis. They are also suitable for the treatment of disorders of the central nervous system such as states of anxiety, tension and depression, central nervous system-related sexual dysfunctions and sleep disorders, and for the regulation of pathological disorders of the absorption of food, tea, coffee, etc. and addictive drugs.
Furthermore, the active compounds are also suitable for regulating the cerebral circulation and are thus effective agents for the control of migraine.
They are also suitable for the prophylaxis and control of the sequellae of cerebral infarcts (cerebral apoplexy), such as stroke, cerebral ischaemias and craniocerebral trauma. The compounds of the formula (I) according to the invention can likewise be employed for the control of painful conditions.
The compounds according to the invention moreover have anti-inflammatory action and can therefore be employed as anti-inflammatory agents.
The invention moreover includes the combination of the compounds of the formula (I) according to the invention with organic nitrates and NO donors.
Organic nitrates and NO donors in the context of the invention are generally substances which display their therapeutic action via the release of NO or NO species. Sodium nitroprusside, nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, molsidomine and SIN-1 are preferred.
The invention moreover includes the combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP). These are, in particular, i5 inhibitors of phosphodiesterases 1, 2 and 5; nomenclature according to Beavo and
Reifsynder (1990) TiPS 11 pp. 150 to 155. By means of these inhibitors, the action of the compounds according to the invention is potentiated and the desired pharmacological effect is increased.
Biological investigations
Vasorelaxant action in vitro
Rabbits are stunned by a blow to the neck and exsanguinated. The aorta is removed, freed from adherent tissue, divided into rings 1.5 mm wide and individually transferred under a pretension to 5 ml organ baths containing carbogen-acrated
Krebs-Henseleit solution of the following composition (mM) at 37°C: NaCl: 119;
KCl: 4.8; CaCl; x 2 HO: 1; MgSO, x 7 HO; 1.4; KH,PO4: 1.2; NaHCO;:25; Glucose: 10. The contractile force is determined using Statham UC2 cells, amplified and digitalized by means of A/D converters (DAS-1802 HC, Keithley Instruments Munich), and recorded in parallel on linear recorders. To produce a contraction, phenylephrine is added to the bath cumulatively in increasing concentration. After several control cycles, the substance to be investigated is investigated in each further passage in increasing dose in each case and the height of the contraction is compared with the height of the contraction reached in the last previous passage. From this, the concentration is calculated which is necessary in order to reduce the height of the control value by 50% (ICsp). The standard administration volume is 5 ul and the proportion of DMSO in the bath solution corresponds to 0.1%. The result is shown below in Table 1:
Table 1: Vasorelaxant action in vitro
Example No. ICso [uM] rw
Determination of the liver clearance in vitro
Rats are anesthetized, heparinized, and the liver is profused in situ via the portal artery.
Ex vivo, the primary rat hepatocytes are then obtained from the liver by means of collagenase solution. 2-10° hepatocytes per ml were incubated at 37°C with the same concentration in each case of the compound to be investigated. The decrease of the substrate to be investigated over time was determined bioanalytically (HPLC/UV,
HPLC/fluorescence or LC/MSMS) at 5 points in time in each case in the period from 0-15 min after the start of incubation. From this, the clearance was calculated by means of the cell count and liver weight.
Determination of the plasma clearance in vivo
The substance to be investigated is administered intravenously to rats via the tail vein as a solution. At fixed points in time, blood is taken from the rats, heparinized and plasma is obtained therefrom by conventional measures. The substance is quantified bioanalytically in the plasma. The pharmacokinetic parameters are calculated from the plasma concentration-time courses determined in this way by means of conventional non-compartmental methods used for this purpose.
The present invention includes pharmaceutical preparations which, in addition to non- toxic, inert pharmaceutically suitable vehicles, contains the compounds of the formula (I) according to the invention, and processes for the production of these preparations.
The active compound can optionally also be present in microencapsulated form in one or more of the vehicles indicated above.
The therapeutic reactive compound of the formula (I) should be present in the abovementioned pharmaceutical preparations in a concentration of approximately 0.1 to 99.5% by weight, preferably of approximately 0.5 to 95% by weight, of the total mixture.
Apart from the compounds of the formula (I) according to the invention, the abovementioned pharmaceutical preparations can also contain further pharmaceutical active compounds.
In general, it has proven advantageous both in human and in veterinary medicine to administer the active compound according to the invention in total amounts of approximately 0.01 to approximately 700, preferably 0.01 to 100, mg/kg of body weight every 24 hours, if appropriate in the form of several individual doses, to achieve the desired results. An individual dose contains the active compound according to the invention preferably in amounts from approximately 0.1 to approximately 80, in particular 0.1 to 30, mg/kg of body weight.
The present invention is shown below in greater detail with the aid of non-restricting preferred examples. If not stated otherwise, all quantitative data relate to percentages by weight.
Abbreviations:
RT: room temperature
EA: ethyl acetate
MCPBA: m-chloroperoxybenzoic acid
BABA: n-butyl acetate/n-butanol/glacial acetic acid/phosphate buffer pH 6 (50:9:25.15; org. phase)
DMF: N.,N-dimethylformamide
Eluent for thin-layer chromatography:
T1 El: toluene - ethyl acetate (1:1)
T1 EtOH1: toluene — methanol (1:1)
Cl EL cyclohexane — ethyl acetate (1:1)
Cl E2: cyclohexane — ethyl acetate (1:2)
Methods for determining the HPLC retention times and preparative methods of separation:
Method A = (LC-MS):
Mobile phase: A = acetonitrile + 0.1% formic acid,
B = water + 0.1% formic acid
Flow: 25 ml/min
Temperature: 40°C
Packing material: Symmetry C 18, 50 x 2.1 mm, 3.5 um.
CR LS LA of
EE J LS wow wm ew
Method B (preparative HPLC):
Mobile phase: A = Milli-Q water + 0.6 g of concentrated hydrochloric acid on 11H,O
B = acetonitrile
Flow: 50 ml/min
Temperature: room temperature
Packing material: YMC-Gel ODS-AQS 11 pm 250 xX 30 mm :
EI CS LA
EA LR
EE CO LA
EL J LN
EI LI LI
S17 -
Starting compounds:
I. Synthesis of 4-[(dimethylamino)methylene]-pyridineacetonitrile (E/Z mixture)
CN h AN
X
~
N
7.52 g (63. 7mmol) of 4-pyridylacctonitrilc and 11.09 g (63.7 mmol) of tert- butoxybis(dimethylamino)methane were stirred at 100°C for 2 h. In the course of this, liberated dimethylamine and t-butanol were led off to the atmosphere by a slight reduced pressure flow by means of a vacuum pump. Flash chromatography (CH,Cly/ethyl acetate 50:1 -> 20:1) yielded the title compound.
Yield: 10.2 g (93%)
Re 0.29 (CH,CI/EA 20/1) 'H-NMR: (300 MHz, D¢-DMSO), 6 = 3.25 (s, 6 H, 2 x CHj3), 7.25 (d, 2 H,
Ar-H), 7.80 (s, 1 H, Ar-H), 8.33 (d, 2 H, Ar-H).
MS: (ESI pos.), m/z = 174 (M+H]")
II. Synthesis of 3-[(dimethylamino)methylene]-pyridineacetonitrile (E/Z mixture)
N
EE
IAN
~N 3.00 g (254 mmol) of 3-pyridylacetonitrile and 4.23 g (25.4 mmol) tert- butoxybis(dimethylamino)methane were stirred at 100°C for 2 h. In the course of this, liberated dimethylamine and t-butanol were led off to the atmosphere by a slight reduced pressure flow by means of a vacuum pump. After cooling, the deposited solid was filtered, washed with a little H,O and the title compound was thus obtained.
Yield: 4.23 g (96%)
Ry: 0.27 (CH,Cl,/MeOH 40/1) "H-NMR: (300 MHz, D¢-DMSO), 6 = 3.08 (s, 3 H, CH3), 3.25 (s, 3 H, CH3), 7.29 (dd, 1 H, Ar-H), 7.57 (s, 1 H, =C-H), 7.66 (dt, 1 H, Ar-H), 8.26 (d, 1 H, Ar-H), 8.54 (d, 1 H, Ar-H).
LCMS: Ret. time: 0.33 min (column: Symmetry, C-18, 3.5 um, 50X2.1 mm, flow 0.5 ml/min, 40°C, gradient: water (+0.1% formic acid): acetonitrile (+0.1% formic acid) at 0 min: 90:10, at 7.5 min 10:90));
MS: (ESI pos.), m/z = 174 ((M+H]")
III. Synthesis of 1-(2-fluorobenzyl)1H-pyrazolo[3,4-b]pyridine-3-carbox- amidine lIA) Ethyl 5-amino-1-(2-fluorobenzyl)-pyrazole-3-carboxylate oy
HNN
\ 0 " J cH, 100 g (0.613 mol) of sodium salt of ethyl cyanopyruvate (preparation analogously to
Borsche and Manteuffel, Liebigs Ann. 1934, 512, 97) are treated with 111.75 ¢g (75 ml, 0.98 mol) of trifluoroacetic acid at room temperature in 2.51 of dioxane under argon with good stirring and the mixture is stirred for 10 min, a large part of the starting material going into solution. 8593g (0.613 mol) of 2-fluorobenzylhydrazine are then added and the mixture is boiled overnight. After cooling, the deposited crystals of sodium trifluoroacetate are filtered off with suction, washed with dioxane and the solution is reacted further in crude form.
IIIB) Ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate
Cr
N Ney 4 \ /
SL
J \—CH,
The solution obtained from 3A) is treated with 61.25 ml (60.77 g, 0.613 mol) of dimethylaminoacrolein and 56.28 ml (83.88 g, 0.736 mol) of trifluoroacetic acid and boiled under argon for 3 days. The solvent is then evaporated in vacuo, the residue is added to 21 of water and the mixture is extracted three times with 11 of ethyl acetate each time. The combined organic phases are dried using magnesium sulphate and concentrated in a rotary evaporator. The residue is chromatographed on 2.5 g of silica gel and eluted with a toluene/toluene-ethyl acetate=4:1 gradient. Yield: 91.6 g (49.9% of theory over two steps).
M.p. 85°C
R¢ (SiO,, T1E1): 0.83
IC) 1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide
Sg
N Ny 4 \ / ——
NH,
Oo 10.18 g (34 mmol) of the ester obtained in Example 3B) are introduced into 150 ml of methanol saturated with ammonia at 0-10°C. The mixture is stirred at room temperature for two days and then concentrated in vacuo.
R¢ (SiO, TIE): 0.33
IID) 3-Cyano-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine ar
N
N N
/4 \ / — \
A\
N
36.1 g (133 mmol) of 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide from Example 3C) are dissolved in 330 ml of THF and treated with 27 g (341 mmol) of pyridine. 47.76 ml (71.66 g, 341 mmol) of trifluoroacetic anhydride are then added in the course of 10 min, the temperature rising to 40°C. The mixture is stirred overnight at room temperature. The batch is then added to 1 1 of water and extracted three times with 0.51 of ethyl acetate each time. The organic phase is washed with saturated sodium hydrogencarbonate solution and with 1 N HCI, dried using MgSO4 and concentrated in a rotary evaporator.
Yield: 33.7 g (100% of theory)
M.p: 81°C
R¢ (Si0,, T1E1): 0.74
HIE) Methyl (2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidate
Cr
N Nan 4 \ /
Hc-O 30.37 g (562 mmol) of sodium methoxide are dissolved in 1.51 of methanol and 36.45 g (144.5 mmol) of 3-cyano-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine (from Example 3D) are added. The mixture is stirred at room temperature for 2 hours and the solution obtained is employed directly for the next step.
IIIF) 1-(2-Fluorobenzyl)lH-pyrazolo[3,4-b]pyridine-3-carboxamidine ar
N NNN
A
CHL
\
NH H
HCI
-02.
The solution of methyl (2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidate obtained from Example 2E) in methanol is treated with 33.76 ¢ (32.19 ml, 562 mmol) of glacial acetic acid and 9.28 g (173 mmol) of ammonium chloride and stirred overnight under reflux. The solvent is evaporated in vacuo, the residue is triturated well with acetone and the deposited solid is filtered off with suction. "H-NMR (dg-DMSO, 200 MHz): 8= 5.93 (s, 2H); 7.1-7.5 (m, 4 H); 7.55 (dd, 1H); 8.12 (dd, 1H); 8.30 (dd, 1H); 9.5 (bs, 4H-exchangeable) ppm.
MS (EI): m/z = 270.2 (M-HCl)
IV. Synthesis of 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4- pyridinyl)-4,6-pyrimidinediol
Be
Naw N,
NN
— OH
HO pa
CN
327¢ (12.1 mmol) of 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3- carboximideamide from Ex. III are suspended in 40 ml of toluene, admixed with 2.88 g (12.1 mmol) of diethyl 2-(4-pyridinyl)malonate (commercially available from
Mercachem) and stirred at 140°C overnight. To work up, the precipitated solid was filtered off with suction and dried in a high vacuum.
Yield: 2.43 g (43%)
LC-MS: R{ = 2.69 min (method A).
MS (ESI pos.), m/z = 415 ((M+H]").
V. Synthesis of 3-[4,6-dichloro-5-(4-pyridinyl)-2-pyrimidinyl]-1-(2-fluoro- benzyl)-1H-pyrazolo[3,4-b]pyridine = 0
ANG
NT
— Ci 0
C) =N 2.39 g (5.77 mmol) of 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-(4- pyridinyl)-4,6-pyrimidinediol from Ex. IV are dissolved in 10 ml of phosphoryl chloride. 3 drops of DMF were added, and the mixture was refluxed for 3 h with stirring. To work up, the reaction solution was concentrated and dried under high vacuum.
Yield: 0.67 g (24%)
LC-MS: Ri = 4.34 min (method A).
MS (ESI pos.), m/z = 451 ([M+H]", Cl;).
Examples 1. 2-[1-[(2-Fluorophenyl)methyl]-1H-pyrazolo[3.4-b]pyridin-3-yl]-5-(4- pyridinyl)-4-pyrimidinamine
N=—
Sr \ N
N /
Si 39
N N
0 0.50 g (1.9 mmol) of I-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridine-3-carboximid- amide from Ex. III and [(dimethylamino)methylene]-pyridineacetonitrile (0.32 g, 1.9 mmol) from Ex. I were suspended in xylene and treated with BF;xOEt; (71 ul, 79 mg, 0.56 mmol, 0.3 equiv.). After 19 h at 140°C, the mixture was allowed to cool to room temperature and concentrated in vacuo. It was possible to purify the title compound by flash chromatography on silica gel (CH,Cl;:MeOH 20:1) and subsequent extraction by stirring in acetonitrile.
Yield: 0.24 g (33%)
Re: 0.17 (EA/MeOH 20:1)
B.p: 254°C
Retention time: 2.7 min (column: Symmetry, C-18, 3.5 wm, 50X2.1 mm, flow 0.5 ml/min, 40°C, gradient: wasser (+0.1% formic acid): acetonitrile (40.1% formic acid) at 0 min: 90:10, at 7.5 min 10:90)) "H-NMR: (300 MHz, Dg-DMSO), § = 5.81 (s, 2H, CH), 7.0-7.6 (m, 9 H, Ar-H,
NH,), 8.64 (m,, 3 H, Ar-H), 9.05 (d, 1 H, Ar-H)
MS: (ESI pos.), m/z = 398 ((M+H]"), (ESI neg.), m/z = 396 ((M-H]")
2. 2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-(4- pyridinyl)-4-pyrimidinamine
Be
NS N,
NN oo NH, pS — 4.00 g (14.9 mmol) of 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximid- amide from Ex. III and 3-[(dimethylamino)methylene]-pyridineacetonitrile (2.57 g, 14.9 mmol) from Ex. II were suspended in xylene. After 12 h at 120°C, the mixture was allowed to cool to room temperature and the deposited precipitate was filtered.
The mother liquor was purified by preparative HPLC (column: Cromsil 120 ODS,
C-18, 10 pum, 250x30 mm, flow 50 ml/min, room temperature, gradient: water acetonitrile at 0 min: 90:10, at 28 min 5:95). The purification process had to be repeated.
Yield: 0.024 g (0.4%)
Re: 0.17 (EA/MeOH 20:1) "H-NMR: (200 MHz, Ds-DMSO), & = 5.81 (s, 2H, OCHa,), 6.95-7.6 (m, 8 H,
Ar-H, NH), 7.92 (dt, 1 H, Ar-H), 8.21 (S, 1H, Ar-H), 8.6-8.75 (m, 2 H, Ar-H), 9.03 (dd, | H, Ar-H).
LCMS: Ret. time: 2.66 min (column: Symmetry, C-18, 3.5 pm, 50X2.1 mm, flow 0.5 ml/min, 40°C, gradient: water (+0.1% formic acid): aceto- nitrile (+0.1% formic acid) at 0 min: 90:10, at 7.5 min 10:90)); MS: (ESI pos.), m/z = 398 (IM+H]"), (ESI neg.), m/z = 396 ([M-H]")
3. 6-Chloro-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4- pyridinyl)-4-pyrnimidinylamine
F
—
Na N,
Cy — Cl
HN
& =N 200mg (0.443 mmol) of 3-[4,6-dichloro-5-(4-pyridinyl)-2-pyrimidinyl]-1-(2- fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine from Ex. V are suspended in 5 ml of 25% aqueous ammonia solution and stirred in an autoclave at 140°C under autogenous pressure overnight. The mixture was extracted three times with dichloromethane and the combined extracts were dried over magnesium sulphate and concentrated to dryness. The residue was chromatographed over silica gel with 30:1 dichloromethane/methanol. For further purification, the crude product was purified by preparative HPLC (method B).
Yield: 34 mg (15%)
Rf 0.45 (CH,Cl,/MeOH 20:1) "H-NMR: (300 MHz, D¢-DMSO), 6 = 5.85 (s, 2H, CH,), 7.10-7.48 (m, 9H, 7Ar-H and NH,), 8.61-8.75 (m, 3H, Ar-H), 8.99 (dd, 1H, Ar-H).
LC-MS: R{ = 3.55 min (method A).
MS (ESI pos.), m/z = 432.3 ((M+H]"), 885.2 ([2M+Na]").
4. 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3.4-blpyridin-3-yl1-5-(4-pyridinyl)-4.6- pyrimidinediamine
Be
Na N,
Ly
NN
~
H,N _) \s 200mg (0.443 mmol) of 3-[4,6-dichloro-5-(4-pyridinyl)-2-pyrimidinyl]-1-(2- fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine from Ex. V are suspended in 5 ml of 25% aqueous ammonia solution and stirred in an autoclave at 140°C under autogenous pressure overnight. The mixture was extracted three times with dichloromethane and the combined extracts were dried over magnesium sulphate and concentrated to dryness. The residue was chromatographed over silica gel with 30:1 dichloromethane/methanol. For further purification, the crude product was purified by preparative HPLC (method B).
Yield: 45 mg (20%)
R¢ 0.30 (CH,Cl/MeOH 20:1) "H-NMR: (300 MHz, Ds-DMSO), 6 = 5.82 (s, 2H, CH,), 6.02 (br.s, 4H, NH), 7.08-7.48 (m, 7H, Ar-H), 8.57-8.68 (m, 3H, Ar-H), 9.13 (dd, 1H,
Ar-H).
LC-MS: R; = 2.55 min (method A).
MS (ESI pos.), m/z = 413.3 ((M+H]"), 847.8 ([2M+Na]").
Claims (17)
1. Compounds of the formula (I) 1 R NH, a \_/ N ~~ 7 0) N V “N N : in which R' represents 4-pyridinyl or 3-pynidinyl; R? represents H, NH; or halogen; and salts, isomers and hydrates thereof.
2. Compounds according to Claim 1, in which R! represents 4-pyridinyl or 3-pyridinyl; R’ represents H, NH, or Cl; and salts, isomers and hydrates thereof.
3. Compounds according to Claim 1, in which R' represents 4-pyridinyl or 3-pynidinyl; R’ represents H; and salts, isomers and hydrates thereof.
4. Process for the preparation of the compound of the formula I, comprising the reaction of the compound of the formula (IT) NH H,N SS N \ “N N (In F A) with a compound of the formula (IIT) N SN R' (IN) where R! 1s as defined above;
if appropriate in an organic solvent, with heating to give the compound of the formula (I); or B) with a compound of the formula (IV) oO 0 100 oc, (av) rR’ where R' is as defined above; in an organic solvent, with heating to give compounds of the formula (V) 0 Na N,
Pv. MV) N Nd \ — OH HO Ls where R! is as defined above;
subsequently with a halogenating agent to give compounds of the formula (VI) 0) Na N, Pw (V1) N 1 ~/ F’ RZ Rr! ° where R' is as defined above; R’ represents halogen; and also finally with aqueous ammonia solution with heating under elevated pressure.
5. Compound of the formula (I) for the treatment of diseases.
6. Medicaments comprising at least one compound of the formula (I) according to Claim 1.
7. Process for the production of medicaments, characterized in that the compound of the formula (I) according to Claim 1 is brought into a suitable administration form, if appropriate using customary excipients and additives.
8. Medicaments comprising the compound of the formula (I) according to Claim 1 in combination with organic nitrates or NO donors.
9. Medicaments comprising the compound of the formula (I) according to Claim 1 in combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP).
10. Use of the compound of the formula (I) according to Claim l in the production of medicaments for the treatment of cardiovascular disorders.
11. Use of the compound of the formula (I) according to Claim 1 in the production of medicaments for the treatment of hypertension.
12. Use of the compound of the formula (I) according to Claim 1 in the production of medicaments for the treatment of thromboembolic disorders and ischaemias.
13. Use of the compound of the formula (I) according to Claim 1 in the production of medicaments for the treatment of sexual dysfunction.
14. Use of the compound of the formula (I) according to Claim 1 in the production of medicaments having anti-inflammatory properties.
15. Use of compounds of the general formula (I) according to Claim 1 in the production of medicaments for the treatment of disorders of the central nervous system.
16. Use according to one of Claims 8 to 13, where the compound of the formula (I) according to Claim 1 is employed in combination with organic nitrates or NO donors or in combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP).
17. The compound described with reference to any one of examples 1 to 4 with regard to the proportions of the constituents.
AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10057753 | 2000-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200303887B true ZA200303887B (en) | 2004-06-21 |
Family
ID=7664122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200303887A ZA200303887B (en) | 2000-11-22 | 2003-05-19 | Novel pyridine-substituted pyrazolopyridine derivatives. |
Country Status (12)
Country | Link |
---|---|
KR (1) | KR20030065519A (en) |
DE (2) | DE10131987A1 (en) |
DO (1) | DOP2001000291A (en) |
EC (1) | ECSP034616A (en) |
GT (1) | GT200100235A (en) |
HN (1) | HN2001000261A (en) |
MY (1) | MY127212A (en) |
PE (1) | PE20020581A1 (en) |
RU (1) | RU2003118584A (en) |
SV (1) | SV2003000743A (en) |
UA (1) | UA74404C2 (en) |
ZA (1) | ZA200303887B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102485724B (en) * | 2010-12-06 | 2015-08-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Substituted thiophene base pyrazolo-pyridines and medicinal use thereof |
JP6189315B2 (en) | 2011-11-25 | 2017-08-30 | アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Process for the preparation of substituted 5-fluoro-1H-pyrazolopyridines |
CN110022871A (en) * | 2016-10-11 | 2019-07-16 | 拜耳制药股份公司 | Combination product comprising sGC stimulant and mineralocorticoid receptor antagonists |
-
2001
- 2001-07-02 DE DE10131987A patent/DE10131987A1/en not_active Withdrawn
- 2001-11-09 DE DE50106655T patent/DE50106655D1/en not_active Expired - Lifetime
- 2001-11-09 RU RU2003118584/04A patent/RU2003118584A/en not_active Application Discontinuation
- 2001-11-09 KR KR10-2003-7006853A patent/KR20030065519A/en not_active Application Discontinuation
- 2001-11-09 UA UA2003065752A patent/UA74404C2/en unknown
- 2001-11-20 DO DO2001000291A patent/DOP2001000291A/en unknown
- 2001-11-20 MY MYPI20015302A patent/MY127212A/en unknown
- 2001-11-21 SV SV2001000743A patent/SV2003000743A/en unknown
- 2001-11-21 HN HN2001000261A patent/HN2001000261A/en unknown
- 2001-11-21 PE PE2001001161A patent/PE20020581A1/en not_active Application Discontinuation
- 2001-11-22 GT GT200100235A patent/GT200100235A/en unknown
-
2003
- 2003-05-19 ZA ZA200303887A patent/ZA200303887B/en unknown
- 2003-05-21 EC EC2003004616A patent/ECSP034616A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20030065519A (en) | 2003-08-06 |
GT200100235A (en) | 2002-06-25 |
DE50106655D1 (en) | 2005-08-04 |
MY127212A (en) | 2006-11-30 |
UA74404C2 (en) | 2005-12-15 |
HN2001000261A (en) | 2002-01-30 |
RU2003118584A (en) | 2004-12-20 |
PE20020581A1 (en) | 2002-07-13 |
DOP2001000291A (en) | 2002-12-15 |
ECSP034616A (en) | 2003-06-25 |
SV2003000743A (en) | 2003-01-13 |
DE10131987A1 (en) | 2002-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6693102B2 (en) | Pyridine-substituted pyrazolopyridine derivatives | |
US7317016B2 (en) | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | |
CA2485143C (en) | Carbamate-substituted pyrazolopyridines | |
CA2485872C (en) | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)-5-(4-pyridinyl)-4-pyrimidinamines and the use thereof as guanylate cyclase stimulators | |
US20040235863A1 (en) | Morpholine-bridged pyrazolopyridine derivatives | |
US20040067937A1 (en) | Novel sulfonamide-substituted pyrazolopyridine derivatives | |
CA2429309A1 (en) | Novel carbamate-substituted pyrazolopyridine derivatives | |
CA2544621A1 (en) | Novel combination containing a stimulator of soluble guanylate cyclase and a lipid-lowering substance | |
ZA200303887B (en) | Novel pyridine-substituted pyrazolopyridine derivatives. |